Clinical and laboratory characteristics of pediatric GCB and non-GCB DLBCL
Characteristic . | GCB, no. (%) . | non-GCB, no. (%) . | P . |
---|---|---|---|
Sex | NS | ||
Male | 25 (58.1) | 5 (55.6) | |
Female | 18 (41.9) | 4 (44.4) | |
Age | NS | ||
1-9 years | 18 (41.9) | 2 (22.2) | |
At least 10 years | 25 (58.1) | 7 (77.8) | |
CNS* | NS | ||
Positive | 1 (2.3) | 1 (11.1) | |
Negative | 40 (93.0) | 8 (88.9) | |
BM | NS | ||
Positive | 0 (0) | 0 (0) | |
Negative | 43 (100) | 9 (100) | |
Bone | NS | ||
Positive | 4 (9.3) | 0 (0) | |
Negative | 39 (90.7) | 9 (100) | |
Stage | NS | ||
1 | 9 (20.9) | 2 (22.2) | |
2 | 12 (27.9) | 2 (22.2) | |
3 | 21 (48.8) | 5 (55.6) | |
4 | 1 (2.3) | 0 (0) | |
LDH* | NS | ||
Less than 500 U/L | 33 (76.7) | 5 (55.6) | |
At least 500 U/L | 9 (20.9) | 3 (33.3) | |
Extranodal involvement | NS | ||
No | 37 (86.0) | 6 (14.0) | |
Yes | 9 (100) | 0 (0) |
Characteristic . | GCB, no. (%) . | non-GCB, no. (%) . | P . |
---|---|---|---|
Sex | NS | ||
Male | 25 (58.1) | 5 (55.6) | |
Female | 18 (41.9) | 4 (44.4) | |
Age | NS | ||
1-9 years | 18 (41.9) | 2 (22.2) | |
At least 10 years | 25 (58.1) | 7 (77.8) | |
CNS* | NS | ||
Positive | 1 (2.3) | 1 (11.1) | |
Negative | 40 (93.0) | 8 (88.9) | |
BM | NS | ||
Positive | 0 (0) | 0 (0) | |
Negative | 43 (100) | 9 (100) | |
Bone | NS | ||
Positive | 4 (9.3) | 0 (0) | |
Negative | 39 (90.7) | 9 (100) | |
Stage | NS | ||
1 | 9 (20.9) | 2 (22.2) | |
2 | 12 (27.9) | 2 (22.2) | |
3 | 21 (48.8) | 5 (55.6) | |
4 | 1 (2.3) | 0 (0) | |
LDH* | NS | ||
Less than 500 U/L | 33 (76.7) | 5 (55.6) | |
At least 500 U/L | 9 (20.9) | 3 (33.3) | |
Extranodal involvement | NS | ||
No | 37 (86.0) | 6 (14.0) | |
Yes | 9 (100) | 0 (0) |
The clinical characteristics were compared between the GCB and non-GCB subgroups. The number of patients of which the clinical information was available and the percentage is shown (Fisher exact or χ2 test).
Data not available for all patients.